Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Neurofibromatosis | Research

Segmental schwannomatosis: characteristics in 12 patients

Authors: Abdulqader Alaidarous, Beatrice Parfait, Salah Ferkal, Joëlle Cohen, Pierre Wolkenstein, Juliette Mazereeuw-Hautier

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Segmental schwannomatosis is characterized by multiple schwannomas affecting one-limb or less than 5 contiguous segments of spine. Its characteristics are not well described in the literature. Our objective was to better describe the demographic and clinical characteristics of this condition.

Methods

This was a retrospective, bi-center study conducted in two French expert centers for neurofibromatosis and schwannomatosis. The clinical, radiographic, pathological and molecular aspects were extracted from patients’ clinical records.

Results

Twelve patients with segmental schwannomatosis were identified. Eight were female and 4 were male. The median age at initial symptom was 29 years (range: 6–60 years) and the median age at diagnosis was 34.5 years (range: 13–65 years). Pain was the initial symptom for the majority of patients (7 of 12). The number of tumors was variable with six patients having more than 10 tumors. Peripheral distribution was seen in all patients. Quality of life could be impaired (median Dermatology Life Quality Index score was 4.5 (range: 2–13). The median duration of follow up was 3 years (range: 1–26). Chronic pain was the main complication (9 of 12 patients). Surgical intervention to control chronic pain was performed for 9 patients of whom 5 experienced recurrence of tumors. Molecular investigations revealed heterozygous LZTR1 variants in 3 of 9 patients.

Conclusion

Segmental schwannomatosis is a rare condition that may start early in life and often remains undiagnosed for many years. Pain is the main symptom and consequently could impair the quality of life. Surgery seems to be effective, but recurrences are frequent. Some patients carried heterozygous LZTR1 variants. Further studies are needed to better understand this rare condition.
Literature
1.
go back to reference Smith MJ, Kulkarni A, Rustad C, Bowers NL, Wallace AJ, Holder SE, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A. 2012;158A:215–9.CrossRef Smith MJ, Kulkarni A, Rustad C, Bowers NL, Wallace AJ, Holder SE, et al. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis. Am J Med Genet A. 2012;158A:215–9.CrossRef
2.
go back to reference Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2010;11:73–80.CrossRef Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, et al. Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2010;11:73–80.CrossRef
3.
go back to reference Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89:1215–9.CrossRef Evans DG, Bowers NL, Tobi S, Hartley C, Wallace AJ, King AT, et al. Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry. 2018;89:1215–9.CrossRef
4.
go back to reference MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology. 1996;46:1072–9.CrossRef MacCollin M, Woodfin W, Kronn D, Short MP. Schwannomatosis: a clinical and pathologic study. Neurology. 1996;46:1072–9.CrossRef
5.
go back to reference MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838–45.CrossRef MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838–45.CrossRef
6.
go back to reference Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006;66:730–2.CrossRef Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006;66:730–2.CrossRef
7.
go back to reference Scott R, Plotkin D, Evans G, et al. Update from the 2011 international Schwannomatosis workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;0:405–16. Scott R, Plotkin D, Evans G, et al. Update from the 2011 international Schwannomatosis workshop: from genetics to diagnostic criteria. Am J Med Genet A. 2013;0:405–16.
8.
go back to reference Jacoby LB, Jones D, Davis K, Kronne D, Short MP, Gusella J, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997;61:1293–302.CrossRef Jacoby LB, Jones D, Davis K, Kronne D, Short MP, Gusella J, et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997;61:1293–302.CrossRef
9.
go back to reference Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805–10.CrossRef Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007;80:805–10.CrossRef
10.
go back to reference Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008;74:358–66.CrossRef Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008;74:358–66.CrossRef
11.
go back to reference Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat. 2008;29:227–31.CrossRef Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat. 2008;29:227–31.CrossRef
12.
go back to reference Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet. 2014;46:182–7.CrossRef Piotrowski A, Xie J, Liu YF, Poplawski AB, Gomes AR, Madanecki P, et al. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet. 2014;46:182–7.CrossRef
13.
go back to reference Hutter S, Piro RM, Reuss DE, Hovestadt V, Sahm F, Farschtschi S, et al. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. Acta Neuropathol. 2014;128:449–52.CrossRef Hutter S, Piro RM, Reuss DE, Hovestadt V, Sahm F, Farschtschi S, et al. Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. Acta Neuropathol. 2014;128:449–52.CrossRef
14.
go back to reference Paganini I, Chang VY, Capone GL, Vitte J, Benelli M, Barbetti L, et al. Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur J Hum Genet. 2015;23:963–8.CrossRef Paganini I, Chang VY, Capone GL, Vitte J, Benelli M, Barbetti L, et al. Expanding the mutational spectrum of LZTR1 in schwannomatosis. Eur J Hum Genet. 2015;23:963–8.CrossRef
15.
go back to reference Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 2015;84:141–7.CrossRef Smith MJ, Isidor B, Beetz C, Williams SG, Bhaskar SS, Richer W, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology. 2015;84:141–7.CrossRef
16.
go back to reference Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschké P, Nectoux J, et al. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology. 2018;20:917–29.CrossRef Louvrier C, Pasmant E, Briand-Suleau A, Cohen J, Nitschké P, Nectoux J, et al. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. Neuro-Oncology. 2018;20:917–29.CrossRef
20.
go back to reference Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRef Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.CrossRef
21.
go back to reference Wang ZX, Chen SL, Yi CJ, Li C, Rong YB, Tian GL. Segmental schwannomatosis in upper-extremity: 5 cases report and literature review. Beijing Da Xue Xue Bao. 2013;45:698–703.PubMed Wang ZX, Chen SL, Yi CJ, Li C, Rong YB, Tian GL. Segmental schwannomatosis in upper-extremity: 5 cases report and literature review. Beijing Da Xue Xue Bao. 2013;45:698–703.PubMed
22.
go back to reference Chen SL, Liu C, Liu B, Yi CJ, Wang ZX, Rong YB, et al. Schwannomatosis: a new member of neurofibromatosis family. Chin Med J. 2013;126:2656–60.PubMed Chen SL, Liu C, Liu B, Yi CJ, Wang ZX, Rong YB, et al. Schwannomatosis: a new member of neurofibromatosis family. Chin Med J. 2013;126:2656–60.PubMed
23.
go back to reference Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17:1317–22.CrossRef Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012;17:1317–22.CrossRef
24.
go back to reference Leverkus M, Kluwe L, Röll EM, Becker G, Bröcker EB, Mautner VF, et al. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis? Br J Dermatol. 2003;148:804–9.CrossRef Leverkus M, Kluwe L, Röll EM, Becker G, Bröcker EB, Mautner VF, et al. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis? Br J Dermatol. 2003;148:804–9.CrossRef
25.
go back to reference Farschtschi S, Mautner VF, Pham M, Nguyen R, Kehrer-Sawatzki H, Hutter S, et al. Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis. Ann Neurol. 2016;80:625–8.CrossRef Farschtschi S, Mautner VF, Pham M, Nguyen R, Kehrer-Sawatzki H, Hutter S, et al. Multifocal nerve lesions and LZTR1 germline mutations in segmental schwannomatosis. Ann Neurol. 2016;80:625–8.CrossRef
26.
go back to reference Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med. 2011;13:576–81.CrossRef Baser ME, Friedman JM, Joe H, Shenton A, Wallace AJ, Ramsden RT, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. Genet Med. 2011;13:576–81.CrossRef
Metadata
Title
Segmental schwannomatosis: characteristics in 12 patients
Authors
Abdulqader Alaidarous
Beatrice Parfait
Salah Ferkal
Joëlle Cohen
Pierre Wolkenstein
Juliette Mazereeuw-Hautier
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1176-4

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue